PL2623604T3 - Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów - Google Patents

Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów

Info

Publication number
PL2623604T3
PL2623604T3 PL12000703T PL12000703T PL2623604T3 PL 2623604 T3 PL2623604 T3 PL 2623604T3 PL 12000703 T PL12000703 T PL 12000703T PL 12000703 T PL12000703 T PL 12000703T PL 2623604 T3 PL2623604 T3 PL 2623604T3
Authority
PL
Poland
Prior art keywords
adenoviral
osteoarthritis
treatment
expression system
based biological
Prior art date
Application number
PL12000703T
Other languages
English (en)
Inventor
Brendan Lee
Kilian Guse
Zhechao Ruan
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of PL2623604T3 publication Critical patent/PL2623604T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/545—IL-1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10071—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL12000703T 2012-02-02 2012-02-02 Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów PL2623604T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20120000703 EP2623604B8 (en) 2012-02-02 2012-02-02 Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis

Publications (1)

Publication Number Publication Date
PL2623604T3 true PL2623604T3 (pl) 2015-07-31

Family

ID=47891791

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12000703T PL2623604T3 (pl) 2012-02-02 2012-02-02 Biologiczny system dostarczania i ekspresji oparty na adenowirusie do zastosowania w leczeniu choroby zwyrodnieniowej stawów

Country Status (12)

Country Link
US (4) US10301647B2 (pl)
EP (1) EP2623604B8 (pl)
JP (2) JP6340320B2 (pl)
CN (1) CN104245941B (pl)
AU (1) AU2013213873B2 (pl)
CA (1) CA2861408C (pl)
DK (1) DK2623604T3 (pl)
EA (1) EA033004B1 (pl)
ES (1) ES2534782T3 (pl)
IN (1) IN2014KN01682A (pl)
PL (1) PL2623604T3 (pl)
WO (1) WO2013114199A1 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014115022A1 (en) 2013-01-25 2014-07-31 Baylor College Of Medicine A helper-dependent adenoviral gene therapy delivery and expression system
GB201410314D0 (en) * 2014-06-10 2014-07-23 Advanced Risc Mach Ltd Display controller
KR20170121291A (ko) * 2015-03-02 2017-11-01 신로직 인코포레이티드 감소된 창자 염증 및/또는 강화된 창자 점막 장벽으로부터 이익을 얻는 질병을 치료하기 위해 공학처리된 박테리아
MX381665B (es) 2016-01-13 2025-03-13 Genzyme Corp Star Vectores aav recombinantes que expresan genes osteoprotectores, que incluyen has2 y lubricina, de utilidad en el tratamiento de la osteoartritis y afecciones articulares relacionadas en mamiferos.
ES2982489T3 (es) 2016-08-19 2024-10-16 Univ Florida Composiciones para el tratamiento de afecciones que utilizan virus adeno-asociados recombinantes autocomplementarios
WO2018071295A1 (en) 2016-10-10 2018-04-19 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inducible production of anti-inflammatory cytokines
US11958886B2 (en) * 2016-12-07 2024-04-16 University Of Florida Research Foundation, Incorporated IL-1RA cDNAs
KR20240093758A (ko) 2017-04-21 2024-06-24 베이롤 칼리지 오브 메드신 종양용해성 바이러스요법 및 면역요법
JP7899083B2 (ja) * 2019-09-18 2026-08-03 パシラ・セラピューティクス・インコーポレイテッド ヒトにおける変形性関節症の処置における使用のための有効用量のアデノウイルスに基づく生物学的送達および発現系、ならびにそれを含む組成物
CN115003698A (zh) * 2019-11-14 2022-09-02 马伦戈治疗公司 抗tcr抗体分子及其用途
CN117280200A (zh) * 2021-05-06 2023-12-22 株式会社理学 X射线造影剂和x射线图像的取得方法
WO2023028492A1 (en) * 2021-08-24 2023-03-02 Pacira Therapeutics, Inc. IL-1Ra GENE THERAPY FOR INTERVERTEBRAL DISC DEGENERATION
KR20250157403A (ko) 2023-03-02 2025-11-04 파시라 테라퓨틱스, 인크. 코르티코스테로이드 치료를 활용한 개선된 아데노바이러스 기반 유전자 요법을 위한 조성물 및 방법
EP4694906A1 (en) * 2023-04-13 2026-02-18 MeiraGTx Gene Regulation Limited Inflammation-inducible promoters

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747072A (en) 1993-07-30 1998-05-05 University Of Michigan Adenoviral-mediated gene transfer to synovial cells in vivo
US20030091536A1 (en) 1999-09-07 2003-05-15 Colorado State University Research Foundation In vivo treatment of joint disease using interleukin-1
FR2806418B1 (fr) * 2000-03-14 2004-07-16 Aventis Pharma Sa Promoteurs hybrides inductibles par l'inflammation, vecteurs les contenant et utilisations
AU2002311777A1 (en) 2001-04-17 2002-10-28 Genetix Pharmaceuticals, Inc. Method of treating arthritis using lentiviral vectors in gene therapy
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
JP2012525154A (ja) * 2009-05-01 2012-10-22 オレゴン ヘルス アンド サイエンス ユニバーシティ 生体内でヒト肝細胞を増大させる方法
SG2014014534A (en) * 2009-05-29 2014-07-30 Xoma Technology Ltd CARDIOVASCULAR RELATED USES OF IL-1ß ANTIBODIES AND BINDING FRAGMENTS THEREOF

Also Published As

Publication number Publication date
EP2623604B1 (en) 2015-02-25
EP2623604A1 (en) 2013-08-07
WO2013114199A1 (en) 2013-08-08
AU2013213873B2 (en) 2018-06-21
US20220073948A1 (en) 2022-03-10
EP2623604B8 (en) 2015-04-22
CN104245941B (zh) 2016-12-07
ES2534782T3 (es) 2015-04-28
JP6340320B2 (ja) 2018-06-06
US20190376080A1 (en) 2019-12-12
AU2013213873A1 (en) 2014-09-25
DK2623604T3 (da) 2015-06-01
US20220348963A1 (en) 2022-11-03
US20150031083A1 (en) 2015-01-29
JP2018075035A (ja) 2018-05-17
JP2015506695A (ja) 2015-03-05
IN2014KN01682A (pl) 2015-10-23
US10301647B2 (en) 2019-05-28
EA033004B1 (ru) 2019-08-30
CA2861408A1 (en) 2013-08-08
WO2013114199A8 (en) 2014-09-25
CA2861408C (en) 2021-10-26
EA201491457A1 (ru) 2014-11-28
CN104245941A (zh) 2014-12-24

Similar Documents

Publication Publication Date Title
EP2623604B8 (en) Adenoviral-based biological delivery and expression system for use in the treatment of osteoarthritis
TWI560299B (en) Surface treatment for stainless steel and housing made thereby
SG10201800720YA (en) Blood treatment systems and methods
GB201115711D0 (en) Phyto-cannabinoids for use in the treatment of cancer
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
EP2858693A4 (en) MEDICAL SUCCION SYSTEM AND DISPOSABLE CONTAINER
GB2509710B (en) Photobioreactor and its use in waste water treatment
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
GB201222455D0 (en) Novel pharmaceutical formulations and their use in the treatment of periodontaldisease
EP2822627A4 (en) STERILIZATION AND HUMIDIFICATION APPARATUS AND INCUBATOR
EP2922536A4 (en) USE OF BUCILLAMINE IN THE TREATMENT OF GOUTTE
ZA201305266B (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma
IL236573A0 (en) Therapeutic retrieval of targets in biological fluids
ZA201500547B (en) Alpha-1-microglobulin for use in the treatment of mitochondria-related diseases
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
GB201001412D0 (en) Propolis and process for the treatment thereof
EP2896294A4 (en) MICRORNA IN HUMAN MILK AND USE THEREOF
GB201218084D0 (en) Novel compounds and methods for use in medicine
ZA201401800B (en) Novel plant defensins and use in the treatment of proliferative diseases
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
GB201322272D0 (en) Catheter and process for cleaning the catheter
GB201201665D0 (en) Heated liquid vessels and components
SI2872176T1 (sl) Karboranilporfirin za uporabo pri zdravljenju raka
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
IL235066A0 (en) Sorcs1 for use in the treatment of obesity and overweight